Results 21 to 30 of about 1,206 (145)

Dimethyl‐, Diethyl‐, and Propylene Carbonates: An Emerging Class of Green Solvents for Organic Synthesis

The Chemical Record, EarlyView.
This review highlights recent advances in the use of organic carbonates, dimethyl carbonate (DMC), diethyl carbonate (DEC), and propylene carbonate (PC), as solvents in organic synthesis. Based on over seventy studies from the past 6 years, it shows their application in different organic reaction types, emphasizing their role in safer and more ...
Gabriela T. Quadros, Livia C. L. Valente, Thiago Barcellos, Daniela Hartwig, Laura Abenante, Eder J. Lenardão   +5 more
wiley   +1 more source

Minimalist, bioinspired and sensorial emulsion based on a Ca2+ double cone vector system using Design of Experiment (DoE)

International Journal of Cosmetic Science, EarlyView.
Development of a biomimetic calcium‐based minimalist skin formulation using Design of Experiment (DoE) to correlate key ingredients' effect on the sensory and physico‐chemical properties of the emulsion. Abstract Objectives Innovation is considered a determining factor in the highly competitive environment of the cosmetic industry to introduce products
Marc Lavarde, Marjorie Lassalle, Solène Gouot, Ysaline Corroyer, Clara Marceau, Vincent Briffaut, Stéphane Poigny, Samar Issa   +7 more
wiley   +1 more source

Exploring the microbiota–skin–brain axis: Chicory extract biotransformed into a postbiotic neurocosmetic enhancer of social and sensory experience

International Journal of Cosmetic Science, EarlyView.
Application of CHICORY EXTRACT by a consumer has the ability to evoke positive emotional responses in individuals who come into tactile contact with the treated skin. Abstract Objective Measuring the influence of cosmetic ingredients on the microbiota‐skin‐brain axis is a difficult challenge.
Stefan Hettwer, Emina Besic Gyenge, Loya Schoeffel, Brigit Suter, Barbara Obermayer   +4 more
wiley   +1 more source

Ozonized Hydrogel and Chlorhexidine Gel for Peri‐Implant Mucositis: A 24‐Month Randomized Controlled Trial

Oral Diseases, EarlyView.
ABSTRACT Objective This randomized controlled trial evaluated the 24‐month effectiveness of a nonsurgical intervention for peri‐implant mucositis, comparing a 15% ozonated sunflower oil hydrogel with a 1% chlorhexidine gel. Methods Thirty patients with 360 peri‐implant mucositis sites were treated in a split‐mouth design, receiving both therapies in ...
Andrea Scribante, Maurizio Pascadopoli, Matteo Pellegrini, Marco Saturnino Lupi, Carlos Pérez‐Albacete Martínez, Andrea Butera   +5 more
wiley   +1 more source

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches

Brain and Behavior, Volume 16, Issue 5, May 2026.
Chronic inflammatory demyelinating polyneuropathy is an autoimmune disorder causing demyelination, leading to distal weakness, sensory loss, and autonomic dysfunction. Immune activation triggers macrophage‐mediated myelin damage and conduction failure.
Ayesha Khan, Arsal Khan, Kuldeep Dalpat Rai, Anzel Saeed, Harsh Kumar, Aneesh Kumar Sangtiani, Tehreem Fatima, Muhammad Tanveer Alam, Faiza Rajput, Sakshi Chawla, Hussain Haider Shah, Humaira Kalam   +11 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Engineering Marker‐Free Lettuce Chloroplast Genome to Express Functional Glucagon‐Like Peptide‐1 Receptor Agonists Exenatide and Lixisenatide

Plant Biotechnology Journal, Volume 24, Issue 5, Page 3158-3171, May 2026.
Engineering of marker‐free lettuce chloroplast genome to express CTB‐Exenatide and CTB‐Lixisenatide for oral delivery. Upper panel: Chemically synthesised exenatide or lixisenatide require expensive production, purification, refrigeration and invasive delivery methods.
Rahul Singh, Henry Daniell
wiley   +1 more source

Computing Network of Diseases and Pharmacological Entities through the Integration of Distributed Literature Mining and Ontology Mapping [PDF]

, 2011
The proliferation of -omics (such as, Genomics, Proteomics) and -ology (such as, System Biology, Cell Biology, Pharmacology) have spawned new frontiers of research in drug discovery and personalized medicine.
Faisal, Fazle Elahi
core   +1 more source

Mesoporous Silica Nanoparticles‐Based Formulations for Enhanced Oral Delivery of Peptide Drugs: A Case Study on Insulin

Small, Volume 22, Issue 24, 27 April 2026.
This work explores the tailored functionalization of mesoporous silica nanoparticles (MSN) to improve the oral delivery of insulin, as a case study. Insulin confinement within silica mesopores increased drug solubility, and co‐formulation with succinylated β‐lactoglobulin yielded pH‐responsive tablets that limited gastric release and proteolysis, while
Claudia Iriarte‐Mesa, Estelle Juère, Andrea Bileck, Thomas Kremsmayr, Michael L. Goodson, Allison Ehrlich, Adnan Hodžić, Martin Kunert, Christopher Gerner, Hanspeter Kählig, Doris Marko, Markus Muttenthaler, David Berry, Giorgia Del Favero, Freddy Kleitz   +14 more
wiley   +1 more source

Dictamen Preliminar de Evaluación de Tecnología Sanitaria N° 032-SDEPFYOTS-DETS-IETSI-2017. Eficacia y seguridad de inmunoglobulina humana en pacientes con polineuropatía desmielinizante inflamatoria crónica idiopática y respuesta inadecuada a corticoides e inmunosupresores [PDF]

, 2017
En este documento se plasma la evaluación de la eficacia y seguridad del uso del producto farmacéutico inmunoglobulina humana en pacientes con polineuropatía desmielinizante inflamatoria crónica idiopática y respuesta inadecuada a corticoides e ...
Burela Prado, Paula Alejandra, Castro Reyes, Maribel Marilú, Corante Zambrano, Matilde, Fiestas Saldarriaga, Fabián Alejandro, Peralta Aguilar, Verónica Victoria, Quispe Huamani, Elder Vicente, Rojas Rodríguez, Francis, Seguro Social de Salud (EsSalud). Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI). Dirección de Evaluación de Tecnologías Sanitarias. Subdirección de Evaluación de Productos Farmacéuticos y otras Tecnologías Sanitarias   +7 more
core